RxDoctor Payments DataLook up a doctor →

Nicolas Chronos, MD

Cardiovascular Disease · Eatonton, GANPI 1427057165

Payments from drug & device makers

$2,376,971in general payments, 2019–2025

Across 897 payments — averaging $2649.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$907K
  • Janssen Research & Development, LLC$669K
  • Modernatx, Inc.$193K
  • Akebia Therapeutics Inc$190K
  • Johnson & Johnson$115K
  • Regeneron$101K
  • plus $202K from 36 others

What the payments were for

  • Speaking & faculty fees$7920%
  • Food & beverage$4,3960%
  • Other$907,16399%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,376,971 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$2,118,209
Medicare patients
1,532
Services billed
31,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban761$919,192
XareltoRivaroxaban207$270,103
EntrestoSacubitril/Valsartan204$228,352
Repatha SureclickEvolocumab259$203,901
OzempicSemaglutide176$192,965
FarxigaDapagliflozin Propanediol180$167,321
MounjaroTirzepatide120$132,190
JardianceEmpagliflozin82$101,759
JanuviaSitagliptin Phosphate64$72,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$40,821
MultaqDronedarone Hcl21$39,561
RybelsusSemaglutide19$34,985
BrilintaTicagrelor42$33,096
Tresiba Flextouch U-200Insulin Degludec12$32,392
TrulicityDulaglutide30$28,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$10,913$925,602777 claims
Johnson & JohnsonXarelto$115,286$270,103207 claims
NovartisEntresto$7,921$228,352204 claims
Novo NordiskOzempic, Rybelsus$458$227,949195 claims
AstraZenecaFarxiga, Brilinta, Symbicort$250$208,212245 claims
Lilly USA, LLCMounjaro, Trulicity$63$160,561150 claims
Boehringer IngelheimJardiance, Tradjenta$15,940$115,25794 claims
MerckJanuvia, Janumet, Belsomra$178$88,97992 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$25,101$73,273102 claims
AbbVieLinzess, Synthroid$12$28,514152 claims
Kowa Pharmaceuticals America, Inc.Livalo$113$25,08641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Eatonton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →